Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Outsourcing in Drug Discovery, 3rd Edition
4.
American Hospital Register
5.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
6.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Tissue Engineering and Stem Cell Technology Report 2007
* * * Latest totally updated market focussed report, available now * * *
Over 160+ pages dedicated to tissue engineering and stem cell analysis.
The market potential of this technology is so huge that revenues may be in excess of $10 billion by 2013. This is a market that you should be part of - NOW!! With a complex regulatory structure still to overcome, yet continued high level investment, many of your competitors are aware of the the commercial opportunities within Tissue Engineering & Stem Cell Technology.
Tissue engineering, the manufacture of complete tissues outside of the body ready for future transplant use, is already with us, including several types of replacement skin and a cartilage substitute. The estimated market for future tissue engineered products including the regeneration of bone, cartilage, and other connective structural treatments is worth approximately $5 billion worldwide.
The report Tissue Engineering and Stem Cell Technology Report 2007 will analyse these two highly lucrative markets for you and will include:
1. An in-depth explanation of the physiology behind stem cell technology
2. A listing of over 100 companies involved and a survey of the principle companies in stem cell development
3. An examination of the products in development & the likely clinical areas for future treatments
4. An in-depth assessment of the future markets delivered to you today
5. A thorough examination of the ethical and regulatory aspects behind stem cell research
6. A detailed analysis of the financial position of the market as it stands and future projections of growth
Methodology
The information contained in this report is from primary industry sources. This includes one-on-one interviews with companies, with governmental bodies and academic insitutions. Analysis has also been drawn from company reports, whether annual financial returns or white papers. The author of this report has dealt with over 50+ companies and industry contacts to assist on the production of this report.
Targeted directly at you this report is designed to be used primarily by executives, investors, venture capitalists, and business development managers and analysts involved in the pharmaceutical or biotechnology areas that may have an interest in stem cell technology.
This market has grown rapidly since the isolation of embryonic stem cells in 1998. With the technologies that impact stem cells catching up to the rate of research, now is your last chance to corner a section of this market.
It is the multifaceted role of stem cells in a whole wide range of diseases that accounts for this huge potential. The diseases that stem cell technology may offer treatments for includes:
1. Parkinsons Disease
2. Diabetes
3. Chronic Heart Disease
4. Kidney Disease
5. Liver Failure
6. Cancer
7. Spinal Cord Injury
8. Multiple Sclerosis
9. Alzheimers Disease
10. Gene Therapy
Why you must buy this report:
The pharmaceutical industry has been seeking the next blockbuster drug, yet it appears as though these might not be as profligate as they have been in the past. However, the tissue engineering & stem cell treatment hold promise. This report analyses the current situation in the market and assesses the potential of work that are currently in the pipeline. You and your company should be part of this market, and you could be by placing your order immediately.
Unique benefits to you when you order this report
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using harddrive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
If you buy one report this year make sure it is the report that will guarantee your success for the forthcoming years. Order this report now.
Publication Date: 28/02/07
Pages: 171
PDF Format
Table of Contents
Price
Single User Licence $1998.00
Department Licence 5 Users $5998.00
Company-wide Intranet Licence $9998.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.